A new Phase III clinical trial (TROPiCS-02 study, NCT03901339), evaluating SG versus standard treatment in ER+/HER2- metastatic breast cancers, has also been initiated recently and is expected to provide data in the near future [45]. Here, ERBB2 is linked to breast carcinoma.